ArticleJournal of virology2002
Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 74 citations in OpenAlex.
- Delineation of a novel assembly intermediate in Rous sarcoma virus integration pathway.Nucleic acids research · 2026Article
- The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario.International journal of molecular sciences · 2023Review
- Retroviral integrase: Structure, mechanism, and inhibition.The Enzymes · 2021Article
- Influence of the amino-terminal sequence on the structure and function of HIV integrase.Retrovirology · 2020Article
- Retroviral DNA Integration.Chemical reviews · 2016Review
- Different Pathways Leading to Integrase Inhibitors Resistance.Frontiers in microbiology · 2016Review
- Intasome architecture and chromatin density modulate retroviral integration into nucleosome.Retrovirology · 2015Article
- HIV-1 integrase multimerization as a therapeutic target.Current topics in microbiology and immunology · 2015Review
- Host Factors in Retroviral Integration and the Selection of Integration Target Sites.Microbiology spectrum · 2014Review
- Review
- The molecular biology of HIV integrase.Future virology · 2012Article
- HIV DNA integration.Cold Spring Harbor perspectives in medicine · 2012Review
- Mutations affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA nuclear import.Retrovirology · 2011Article
- The HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integration.Biochemistry · 2011Article
- HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.Journal of molecular biology · 2011Article
- Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.Acta naturae · 2011Article
- Structural biology of retroviral DNA integration.Virology · 2011Review
- Functional coupling between HIV-1 integrase and the SWI/SNF chromatin remodeling complex for efficient in vitro integration into stable nucleosomes.PLoS pathogens · 2011Article
- Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.Biochemistry · 2010Article
- Authentic HIV-1 integrase inhibitors.Future medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Replication of retroviruses requires integration of the linear viral DNA genome into the host chromosomes. Integration requires the viral integrase (IN), located in high-molecular-weight nucleoprotein complexes termed preintegration complexes (PIC). The PIC inserts the two viral DNA termini in a concerted manner into chromosomes in vivo as well as exogenous target DNA in vitro. We reconstituted nucleoprotein complexes capable of efficient concerted (full-site) integration using recombinant wild-type human immunodeficiency virus type I (HIV-1) IN with linear retrovirus-like donor DNA (480 bp). In addition, no cellular or viral protein cofactors are necessary for purified bacterial recombinant HIV-1 IN to mediate efficient full-site integration of two donor termini into supercoiled target DNA. At about 30 nM IN (20 min at 37 degrees C), approximately 15 and 8% of the input donor is incorporated into target DNA, producing half-site (insertion of one viral DNA end per target) and full-site integration products, respectively. Sequencing the donor-target junctions of full-site recombinants confirms that 5-bp host site duplications have occurred with a fidelity of about 70%, similar to the fidelity when using IN derived from nonionic detergent lysates of HIV-1 virions. A key factor allowing recombinant wild-type HIV-1 IN to mediate full-site integration appears to be the avoidance of high IN concentrations in its purification (about 125 microg/ml) and in the integration assay (<50 nM). The results show that recombinant HIV-1 IN may not be significantly defective for full-site integration. The findings further suggest that a high concentration or possibly aggregation of IN is detrimental to the assembly of correct nucleoprotein complexes for full-site integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.